Saatja: Tartu Ülikool <
[email protected]>
Saadetud: 18.05.2021 12:40
Adressaat: SM Info <
[email protected]>
Teema: Jätkutaotlus 3 uurimistööle "Personaalmeditsiin paremaks
elukvaliteediks proaktiivse modelleerimise abil“ kooskõlastuse saamiseks
Tere!Esitame jätkutaotluse uurimistööle "Personaalmeditsiin paremaks
elukvaliteediks proaktiivse modelleerimise abil.Teiega on jagatud
Webdesktop-i dokumenti, mis asub järgneval aadressil: LugupidamisegaEne
Mö
[email protected] 4050; 507 1174
Eesti b ioeetika ja inimuuringute nõukogu le JÄTKUTAOTLUS nr 3 Uurimistöö täielik nimetus: „Personaalmeditsiin paremaks elukvaliteediks proaktiivse modelleerimise abil“ „ 4Q Personalized Medicine by Predictive Modeling for Better Quality of Life “ Uurimistöö p eamine eesmärk (on sama nagu põhitaotlusel) : Insuldi personaliseeritud haigusriski, ravi, rehabilitatsiooni ja ühiskonda taasintegreerumise mõju hindamiseks ja personaliseeritud lähenemise rakendamiseks luua PRECISE4Q konsortsiumi abil vastavaid insuldi staadiume kajastavad arvutimudelid. Vastutav uurij a (on sama nagu põhitaotlusel) : ees- ja perekonnanimi: Lili Milani teaduslik kraad: PhD amet: epi- ja farmakogenoomika professor , asedirektor töökoht: Genoomika instituut, Tartu Ülikool töökoha aadress: Riia 23b/2-505 telefoninumber: 53045400 e-post:
[email protected] Uuringu läbiviimise lõpptähtaeg on endiselt 28. veebruar 2023. Nimetatud uuringule on varem väljastatud Eesti bioeetika ja inimuuringute nõukogu luba : 13. detsember 2019 nr 1.1-12/2807 (Põhitaotlus, mille tekst koos täiendustega on lisatud antud jätkutaotlusele) 8. detsember 2020 nr 1.1-12/3420 (Jätkutaotlus 1, millega suurendasime valimit kuni 24 000 geenidoonorini , täiendasime andmevälju ja lisasime uusi uurijaid) 13. aprill 2021 nr 1.1-12/3420 (Jätkutaotlus 2, millega muutsime finantsallikat ja täiendasime väljastatavaid andmevälju). Taotluse sisu: Soovime lisada projekti “ Personaalmeditsiin paremaks elukvaliteediks proaktiivse modelleerimise abil ” uue uurija . Kristiina Rannikmäe ülesandeks projektis on andmekaeve abil kogutud info valideerimine ja nende kvaliteedi hindamine . Ta on kliinilise kompetentsiga neuroloog ning teeb koostööd Lili Milani uurimisgrupiga . Temaga sõlmitakse enne andmetele ligipääsu andmist konfidentsiaalsusleping. Ta on projektiga seotud kuni selle lõppemiseni, seega kuni 28. veebruar 2023. Ta saab ligipääsu andmetele andmepilves, nende allalaadimist talle ei võimaldata. Seoses sellega, et tema praegune töökoht on Edinburghi ülikool, kaasatakse uuringusse ka see asutus. Uurimistööga tegeleb vaid Kristiina, sest ülesanne eeldab lisaks spetsiifilistele meditsiiniteadmistele ka eesti keele oskust. Algsesse taotlusesse on lisatud järgmine tekst: punktis 1, lehekülg 1 „ United Kingdom , Edinburgh, Usher Institute of University of Edinburgh “ punktis 2.2, lehekülg 6 given name and surname: Kristiina Rannikmäe Academic degree: PhD Occupation: Senior Clinical Research Fellow Workplace: Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK Phone Number: +44 7808664850 e-mail:
[email protected] punktis 2.4, lehekülg 7 given name and surname of authorized person: Cathie Sudlow Occupation: Professor of Neurology & Clinical Epidemiology in the University of Edinburgh, Director of the BHF Data Science Centre Workplace: NINE Edinburgh BioQuarter, Address: 9 Little France Road, Edinburgh EH16 4UX E-mail:
[email protected] leheküljel 27 lisatud uurija ja instituudi allkirjaõigusliku isiku nimed ja liitumise kuupäevad. Esitatud dokumentide nimekiri Kaaskiri Uurimistöö esialgne taotlus täiendustega Taotluse esitaja kontaktandmed: Lili Milani lili.milani @ut.ee 18 . 0 5 .202 1
RESEARCH APPLICA T ION for the Estonian Committee on Bioethics and Human Research Table of Contents TOC \o "1-3" \h \z \u 1. RESEARCH DATA PAGEREF _Toc22197963 \h 1 2. RESEARCH INVESTIGATORS AND INSTITUTIONS PAGEREF _Toc22197964 \h 2 3. SOURCE OF FINANCE PAGEREF _Toc22197965 \h 6 4. BRIEF REVIEW OF RESEARCH CONDUCTED ON THE SAME TOPIC EARLIER PAGEREF _Toc22197966 \h 7 5. REASONS FOR RESEARCH PLANNED PAGEREF _Toc22197967 \h 8 6. TIME OF CONDUCTING THE STUDY PAGEREF _Toc22197968 \h 9 7. STUDY GROUP AND DESCRIPTION OF RECRUITMENT PAGEREF _Toc22197969 \h 9 8. DESCRIPTION OF RESEARCH METHODOLOGY PAGEREF _Toc22197970 \h 9 9. ANALYSIS OF THE ETHICAL ASPECTS OF THE STUDY PAGEREF _Toc22197971 \h 11 10. INFORMATION ON EARLIER OR SIMULTANEOUS ASSESSMENT OR ON APPROVAL OF THE SAME PROJECT ELSEWHERE PAGEREF _Toc22197972 \h 12 11. ANNEXES PAGEREF _Toc22197973 \h 13 RESEARCH DATA Full title of research project : 4Q Personalized Medicine by Predictive Modeling for Better Quality of Life List of collaborating institutions : Estonia, Tartu, University of Tartu Austria, Graz, University of Graz Spain, Murcia, University of Murcia Spain, Barcelona, QMENTA Germany, Berlin, Charité University Medicine Ireland, Technology University Dublin Germany, AOK Nordost Health Insurance, P otsdam Germany, Berlin, University of Applied Science, Data Science Institute Sweden, L inköping University, Linköping Germany, German Research Center for Artificial Intelligence (DFKI), Saarbrücken . United Kingdom, Edinburgh, Usher Institute of University of Edinburg h RESEARCH INVESTIGATORS AND INSTITUTIONS 2.1. Responsible investigator G iven name and surname: Lili Azin Milani Academic degree: PhD Occupation: Chief Scientist of Epi - and Pharmacogenomics, Head of Core Laboratory Workplace : Institute of Genomics , University of Tartu address: Tartu, Rii a 23b / 2-505, phone number: +372 5304 5400 e-mail:
[email protected] 2.2. Sub-investigators given name and surname: Kadri Ligi Academic degree: MSc bioinformatics Occupation: PhD student Workplace: Institute of Computer Science, chair of data science, University of Tartu Phone Number: + 372 5263362 e-mail:
[email protected] given name and surname: Siim Kurvits Academic degree: Bachelor of Science, Gene technology Occupation: Specialist / Master Student Workplace: University of Tartu Phone Number: +372 5387 1194 e-mail:
[email protected] given name and surname: Ainika Adamson Academic degree: Bachelor of Science in Engineering, Computer Science Occupation: Data Analyst/ Master student Workplace: University of Tartu Phone Number: +372 5661 8502 e-mail:
[email protected] given name and surname: Anu Reigo Academic degree: MD Occupation: Lead Specialist in Medical Genomics Workplace: University of Tartu, Institute of Genomics, Estonian Genome Center Phone Number: +372 737 4040 e-mail:
[email protected] given name and surname : Dage Särg Academic degree: MA (comp uter l inguistics) Occupation: Programmer Workplace: Institute of Computer Science, chair of data science , University of Tartu Address: J. Liivi 2, 50409, Tartu Phone Number: + 372 53811407 E-mail:
[email protected] given name and surname: Sven Laur Academic degree: PhD Occupation: Senior research fellow in secure data mining Workplace: Institute of Computer Science, chair of data science , University of Tartu Address: J. Liivi 2 – 326 Phone Number: + 372 737 5434 E-mail:
[email protected] given name and surname: Toomas Haller Academic degree: PhD Occupation: Senior research er Workplace: Institute of Genomics , University of Tartu Address: Riia 23b / 2, 506, Tartu, Estonia Phone Number: + 372 737 4041 E-mail:
[email protected] given name and surname: JOSE ANTONIO MIÑARRO GIMENEZ Academic degree: PhD Occupation: Post-doctoral researcher Workplace: Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation Address: Auenbruggerplatz 2 Phone Number: (0034) 635813760 E-mail:
[email protected] given name and surname: Catalina Martínez Costa Academic degree: PhD Occupation: Post-doctoral researcher Workplace: Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation Address: Auenbruggerplatz 2 Phone Number: (0043) 69910886354 E-mail:
[email protected] given name and surname: Paulo Rodrigues Academic degree: PhD Occupation: CTO of QMENTA Workplace: QMENTA Job Address: Barcelona, Carrer Roger de Lluria 46 Principal 1a, Barcelona, Spain Phone Number: +34933282007 E-mail:
[email protected] given name and surname: Matthew Rowe Academic degree: PhD Occupation: Neuroimaging engineer Workplace: QMENTA Job Address: Barcelona, Carrer Roger de Lluria 46 Principal 1a, Barcelona, Spain Phone Number: +34933282007 E-mail:
[email protected] given name and surname: Irina Sánchez Academic degree: MSc Occupation: Deep Learning Engineer Workplace: QMENTA Job Address: Barcelona, Carrer Roger de Lluria 46 Principal 1a, Barcelona, Spain Phone Number: +34933282007 E-mail:
[email protected] given name and surname: Dietmar Frey Academic degree: MD Occupation: Coordinator and scientific lead PRECISE4Q Workplace: Predictive Modeling in Medicine Lab, Charité – Universitätsmedizin Berlin Address: Augustenburger Platz 1, 13353 Berlin Germany Phone Number: +49 (0)30 450 560 398 E-mail:
[email protected] given name and surname: Vince Istvan Madai Academic degree: PhD Occupation: Senior Medical AI researcher Workplace: Department of Neurosurgery, Charité Medical University, Berlin, Germany Address: Steegerstr . 8, 13359 Berlin, Germany Phone Number: +49 178 725 31 05 E-mail:
[email protected] given name and surname: Michelle Livne Academic degree: PhD Occupation: ML team lead Workplace: Predictive Modeling in Medicine Lab, Charité – Universitätsmedizin Berlin Address: Augustenburger Platz 1, 13353 Berlin Germany Phone Number: +49-17655601266 E-mail:
[email protected] given name and surname: Tabea Kossen Academic degree: MSC Occupation: Machine Learning Scientist Workplace: Predictive Modeling in Medicine Lab, Charité – Universitätsmedizin Berlin Address: Dessauer Str. 37 – 10963 Berlin, Germany Phone Number: +49 (151) 12784898 E-mail:
[email protected] given name and surname: Hüseyin Camalan Academic degree: BA Occupation: Research Assistant Predictive Modeling in Medicine Group, Charité , Berlin, Germany Workplace: Predictive Modeling in Medicine Lab, Charité – Universitätsmedizin Berlin Address: Augustenburger Platz 1, 13353 Berlin Germany Phone Number: +49 (176) 433 465 03 E-mail:
[email protected] given name and surname: John D Kelleher Academic degree: PhD Occupation: Professor Workplace: Technology University Dublin Address: Greenway Hub, Grangegorman , Dublin, Ireland , D07 H6K8 Phone +353 87 668 4661 E-mail:
[email protected] given name and surname: Thomas Peter Zahn Academic degree: PhD Occupation: professor Workplace: University of Applied Science, Data Science Institute Address: Leibnizstraße 11 – 13,140625 Berlin , Germany. Phone 030 319909516 E-mail:
[email protected] given name and surname: Gunnar Cedersund Academic degree: PhD Occupation: Associate professor and docent, Linköping University, Sweden Workplace: Linköping University Address: SE-581 83 Linköping, Sweden Phone +46-(0)10103-4148 E-mail:
[email protected] given name and surname: Kajsa Tunedal Academic degree: BA Occupation: Teaching assistant in programming, Linköping University Workplace: Linköping University Address: SE-581 83 Linköping, Sweden Phone +46 0706609644 E-mail:
[email protected] given name and surname: Tilda Herrgårdh Academic degree: MSc Occupation: PhD student Workplace: Linköping University Address: SE-581 83 Linköping, Sweden Phone +46 70 220 21 72 E-mail:
[email protected] given name and surname: Günter Neumann Academic degree: PhD Occupation: Professor of Computational Linguistics, Saarland University and Research Fellow at DFKI Workplace: German Research Center for Artificial Intelligence, Saarbrücken , Germany Address: Campus D3 2, Stuhlsatzenhausweg 3, 66123 Saarbrücken , Germany Phone +49 681 85775 5298 E-mail:
[email protected] given name and surname: Saadullah Amin Academic degree: BA Occupation: Junior Researcher, DFKI Workplace: German Research Center for Artificial Intelligence (DFKI), Saarbrücken , Germany Address: Campus D3 1 ( Altbau ), 66123 Saarbrücken , Germany Phone +49 681 85775 5365 E-mail:
[email protected] given name and surname: Kristiina Rannikmäe Academic degree: PhD Occupation: Senior Clinical Research Fellow Workplace: Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK Phone Number: +44 7808664850 e-mail: HYPERLINK "mailto:
[email protected]"
[email protected] 2.3. Head of the investigator-in-charge or his / her representative: given name and surname: Mait Metspalu Occupation : Director of the Institute of Genomics Workplace : Institute of Genomics address: Tartu, Riia 23b-303 , Estonia 2.4 Consent from authorised persons of the partner organisations : given name and surname of authorized person: Professor Andrea Berghold Occupation : Head of the Institute for Medical Informatics, Statistics and Documentation, Workplace : Medical University of Graz address: Graz, Auenbruggerplatz 2, Austria given name and surname of authorized person: Paulo Rodrigues Occupation: CTO of QMENTA Workplace: QMENTA address: Barcelona, Carrer Roger de Lluria 46 Principal 1a, Barcelona, Spain given name and surname of authorized person: Dietmar Frey Occupation: Founding director of the Charité Predictive Modeling in Medicine Lab Workplace: Predictive Modeling in Medicine Lab, Charité – Universitätsmedizin Berlin Address: Augustenburger Platz 1, 13353 Berlin Germany given name and surname of authorized person: Professor John D. Kelleher Occupation: Academic Leader of the ICE Research Institute Workplace: Technology University Dublin address: Research, Enterprise and Innovation, Greenway Hub, Dublin Institute of Technology, Grangegorman Campus, Dublin, Ireland given name and surname of authorized person: Marek Rydzewski Occupation: Head of Health Management Division Workplace: AOK NORDOST - DIE GESUNDHEITSKASSE (AOK NORDOST) Address: BEHLERTSTRASSE 33A, POSTDAM 14456, Germany. given name and surname of authorized person: Thomas Peter Zahn Occupation: professor Workplace: University of Applied Science, Data Science Institute Address: Leibnizstraße 11 – 13,140625 Berlin, Germany given name and surname of authorized person: Gunnar Cedersund Occupation: PI of the ISB Group, Linköping University, Sweden Workplace: Department of Biomedical Engineering, Linköping University. Address: SE-581 83 Linköping, Sweden given name and surname of authorized person: Günter Neumann Occupation: Research Fellow at DFKI Workplace: German Research Center for Artificial Intelligence, Saarbrücken , Germany Address: Campus D3 2, Stuhlsatzenhausweg 3, 66123 Saarbrücken , Germany given name and surname of authorized person: Jesualdo Tomás Fernández Breis Occupation: Professor at Univerity of Murcia Workplace: Faculty of informatics,IMIB -Arrixaca , Murcia, Spain Address: Campus of Espinardo , 30100 Murcia, Spain given name and surname of authorized person: Cathie Sudlow Occupation: Professor of Neurology & Clinical Epidemiology in the University of Edinburgh, Director of the BHF Data Science Centre Workplace: NINE Edinburgh BioQuarter , Address: 9 Little France Road, Edinburgh EH16 4UX E-mail: HYPERLINK "mailto:
[email protected] "
[email protected] 3. SOURCE OF FINANCE Source: H2020-SC1-2016-2017 / H2020-SC1-2017-CNECT-2 Grant Agreement Number 777107; MP1GI18442R and MLTGI18442R (received 2018 ; 01.05.2018 - 30.04.2022). No compensation is paid to the patients involved . The survey concerning the data exchange and connection to the Estonian Biobank of the Institute of Genomics of the University of Tartu (EBB) is based on information contained in databases and study subjects will not be contacted . 4. BRIEF REVIEW OF RESEARCH CONDUCTED ON THE SAME TOPIC EARLIER S troke is the second most common cause of death and the world's leading cause of disability . Large international studies have shown that cardiovascular disease (CVD) has a strong hereditary background and is affected by m any genetic factors. A polygen etic risk score ( P RS) methodology has been developed that can be used in individual risk assessment . A study based on large European cohorts showed that inclusion of genetic risk score makes the estimated risk of CVD more accurate. Unlike many other more common age-related illnesses ( e.g. diabetes and heart disease), there is currently no good preclinical biomarker for stroke. The causes of the disease are largely individual, so it is important to study individual risks. T reatment response is also very different, thus an individual approach to treatment and the rehabilitation process is also important . To estimate personalized risk for stroke , the effect of personalized treatment, rehabilitation and reintegration to society , the PRECISE4Q Consortium will create multiple computer models for patients on various stages along the stroke prevention-patient reintegration line (prevention , acute treatment, r ehabilitation , reintegration into society) . This is the main aim of the planned research. For this purpose, the patients’ genetic and health data from several areas of Europe will be used . This allows to personalize the treatment of stroke according to the needs of the patient and extend the results to a wider population . Thus, it is possible to estimate whether the results obtained in the Consortiums’ individual countries are wider and applicable for the general European population or if additional data needs to be collected . Previous Work Related to Research: The Lead Partner of the consortium has shown excellence in several prediction models for stroke, and the first trial for applying prediction methods in clinical practice in Estonia has been launched . However, a wider view of prevention and its application in Europe is still missing. PRECISE4Q will monitor the results of the following projects as potential input for the stroke prevention models: The clinical flagship project (2017-2019) launched by the Estonian Ministry of Social Affairs for the prevention of cardiovascular disease by applying statin therapy (cholesterol-lowering treatment) and monitor individual indications. University of Tartu, Estonia. “Simulation of the Cerebral Circulation for Prediction of Ischemic Events” (2014-2016) Charité University Medicine, Berlin, Germany “PREDICTioN2020: Simulation-based Prediction of Stroke” (2016-...), a federal-funded project. Charité University Medicine, Berlin, Germany 5. REASONS FOR RESEARCH PLANNED EBB database contains information collected from the gene donors on the basis of a health and genealogy questionnaire filled in at the time of joining the biobank. From this day forward, based on a voluntary consent given by the donor, data have been supplemented from other health databases, such as the database of the eHealth, Health Insurance Fund databases, Estonian Causes of Death Registry , Estonian Cancer Registry, Estonian Population Registry (Human Genes Research Act (HGRA) §24 section 2) . This provides the basis for obtaining sufficient data for creating prevention and treatment models. An example of data required for creating one model is demonstrated in Bushnell et al, 2014. The data has been used in the domestic research project (Precise 4Q Personalised Medicine by Predictive Modeling for Better Quality of Life; permission approval no 289/T-25 - 21.01.2019 obtained by the Institute of Genomics and Institute of Computer Science, University of Tartu from the Research Ethics Committee of the University of Tartu (UT REC). During this research a data table has been created (Annex 11.4; structure of the data table). The selected data fields are necessary for estimating the clinical, life-style and demographic factors that lead to ischemic and sporadic stroke, and are relevant for treatment outcome. The study design ha s been agreed on by the PRECISE4Q Consortium and confirmed by European Commission. The aim of the current research project is to use this data in a pseudonymis ed format in computer modelling processes by PRECISE4Q Consortium partners for building stroke prevention and treatment models. No information that enables neither identification of the donors nor acquiring of additional data will be forwarded to partners. In case additional information is required for the modelling purposes, this will be provided by the Estonian partners and obtained within the domestic research project mentioned above, and prior agreed with the Estonian Committee on Bioethics and Human Research according to the law. The objectives of EBB activities , and thus the PRECISE4Q Consortium, are set out in the HGRA . The study “ Personal Medicine for Better Quality of Life through Preventive Modeling ” is based on the desire to apply genetic research results to improve public health. The aim of the research is to find ways of using personal prevention, treatment and rehabilitation schemes based on gene, phenotype information and he alth data from gene donors. The project is being launched in the field of stroke prevention, treatment and rehabilitation. An in-house study is being carried out where information on the risk of disease ( using data from the database of EBB , previously imported from the gene donor questionnaire, Health Insurance F und, hospital databases, e- H ealth descriptions of epicrises , digital prescriptions, medical records) was collected from the different free text data and summarized in the table (structure of the data table, A nnex 11.4). Some data table entries are not available due to the specificity of free-text data analysis. Only the data table will be forwarded to the project partners . Based on the table , an initial simulation model is created. This serves as an input to the international study aimed at the creation of a platform for the prevention and treatment of virtual and real-time-al tered strokes. In addition to the research carried out in Estonia, PRECISE4Q partners have carried out similar surveys on stroke patients as ours, and all the data will be integrated into computer models. Based on innovative models, a digital stroke platform is set up to support the dynamic assessment of patient's risk of stroke, treatment outcomes, rehabilitation program and reintegration into society. This allows doctors to optimize and, if necessary, correct their prevention and treatment strategies over time. For model l ing, in addition to data from EBB , other partners will provide other data such as information extracted from genetic material – information about gene expression, epigenetics, blood biochemical indicators, microbiome data as well as data contained in disease records, registers and health insurance database and images of brain perfusion studies . Estonian partners work only with information already in the databases, but international partners collect data, including genetic material, from their patients. This is done in accordance with the applicable foreign legal and ethical standards. The lead partner of the consortium is the University of Berlin's Charite Clinic, which also carries out validation of the models being developed for patients. 6. TIME OF CONDUCTING THE STUDY December 2019 - February 2023 7. STUDY GROUP AND DESCRIPTION OF RECRUITMENT FOR THE ESTONIAN COHORT In the initial, domestic study, the cohort size of gene donors with stroke was 2000 gene donors and 2000 as control group based on 50,000 biobank participants available at the time of launch of the study . We anticipate d that this number would increase to max 8,000 cases and 8,000 controls, based on the current sample size of 200,000 participants. As the phenotype data is not available yet for the full cohort, we could only provide estimates. As not all data fields were filled for all gene donors, the exact amount of data that will be shared with the partners differs for each individual. Due to different operations in partner institutions, the number of controls per cases would have to be twice as large as the control group. The maximum number of individuals concerned is therefore 24 ,000. G enome or exom e sequencing and genotype data was used for all EBB gene donors included in the study , health data from national databases added . Age data was also collected. These data were combined with the EBB Database information, and a summary table created . The sample s were obtained from the group of subjects (hereinafter the stroke group) and the matched control cohort (hereinafter control grou p ) . Gene donors with stroke or at risk of th is disease (family or lifestyle risk) were included in the stroke group by adding an equal number of randomi s ed control group gene donors. The control group was randomly selected. The gene donors involved in the control group are not known to have suffered stroke. 8. DESCRIPTION OF RESEARCH METHOD OLOGY The study is carried out in collaboration between University of Tartu, University of Graz, QMENTA, Charité Universitätsmedizin Berlin , Technolog ical University Dublin , AOK Nordost , Univer s ity of Applied Science , University of Linköping and DFKI , a nd requires the exchange of pseudonymis ed data of phenotype s , genotype s and health data summarised in table format as seen in Appendix 11.4 on gene donors for whom stroke or heart attack (or belonging to the risk groups) has been identified . If required, an equal number of randomly selected control group gene donors ’ data will also be included . The criteria for selecting the gene donors involved in the control group are: age and sex matched individuals that ha ve not suffered stroke(ICD-I69-I69) . The EBB issues a general data table that has been obtained by analysing pseudonymis ed medical records, epicri ses . The epicrises ’ data and medical records have previously been obtained by EBB , pseudonymised, and integrated in to the data base of EBB . Additional data and recurrent linking with E-Health databases is not required for carrying out this study . Figure 1 describes data extraction from epicrises as performed in the domestic research project ( permission for research 289/T-25 by the Research Ethics Committee of the University of Tartu for the Institute of Genomics and Institute of Computer Science, University of Tartu ). The epic r ises are XML document s consisting of structured data and free text fields. F inal tables are a result of processing structured data and free text , which is being done within the domestic project . For that we have use d fact extraction piplelines built on top of EstNLTK . Fact extraction is m o stly built on top of rule based methods, as the epicris i s document is semi - structured and rules are easy to write for measurements, drugs, procedures. However, l ifestyle data extraction requires classical ML techniques like SVM and NeuralNetwoks . The TEXTA toolkit is used for inspect ing extracted facts . It is also good for identifying seed ph r ases for concepts . All data table fields are not available for all data subjects. If necessary for modelling purposes, additional information will be extracted within the domestic research project, and the forwarding of another data table agreed with the Estonian Committee on Bioethics and Human Research . In addition to the information available in the EBB database, no additional data is collected . As a result of the research, data are presented in the table (structure of the data table to be created, Annex 11.4) will be distributed to the partners for further research activities . Figure 1. University of Tartu epicrisis data p r o cessing. All investigators, the EBB and the Institute of Computer Science ( ICS ) will ensure proper data processing and protection of gene donors' rights in accordance with the HGRA . The PRECISE4Q Consortium partners will ensure the development of data management and analysis methods. The study uses statistical analysis methods, with emphasis on different types of data integration solutions and analytical methods that allow different "omics" data to be combined. This allows to search for links between different data types and correlations and methods that allow one or more data types to be used for future diagnostic purposes. All data collected from the Estonian gene pool and other databases is encoded and partners have no access to their deanon y mi s ation . The personal data collected in the research are stored at the University of Tartu Science Computing Center servers. Access to data is restricted to the investigator-in-charge and her domestic research team. At the end of the project ( 1. 03 .202 3 ) all the original data tables will be deleted from the PRECISE4Q Consortium partners’ servers . If the generated computer models require original input data, the partners will apply for a renewed permission to store the un identified data in their servers for a longer period . No data tables will be stored for future research by the Partners, as each research project needs a separate permission from the Estonian Committee on Bioethics and Human Research . According to the General Data Protection Regulation, people have the right to decline using their data in research projects. I f the data owners desire that their data is no longer used, the pseud- identifiers will be deleted . At the same time, it is important to note that if summary statistics have been created, the removal of individual data may not be possible. 9. ANALYSIS OF THE ETHICAL ASPECTS OF THE STUDY Samples and data used in the work have been collected previously by the EBB during the creation of the biobank. The involvement of investigators has been in accordance with the HGRA . All gene donors have joined the EBB on a voluntary basis and signed the Gene Donor Consent Form. The authors of the study monitor all generally accepted norms of medical ethics when working with pseudonymis ed health data. The project is carried out on the basis of the HGRA and other legislation concerning the work of the EBB . The investigators follow all generally accepted medical ethics standards when working with pseudonymis ed health data. Pursuant to Section 22 (3) of the HGRA , the chief processor shall designate persons who carry out coding or decoding who have access to gene donor consent, a set of tissue samples and DNA descriptions, health status descriptions and pedigree s, and who issue encoded or un coded tissue samples, DNA descriptions or health status descriptions . This study has been analysed and the four basic principles of bioethics have been taken into account when planning activities. The principle of respect for individual autonomy The main features of the first principle are the voluntary nature of participation in the trial, the existence of written consent and the protection of privacy and personal data. This study will include data from volunteer gene donors with EBB . Gene donors have signed a consent form for joining the EGV, allowing to use their data for different research purposes. IGUS § 12. Consent to becoming a gene donor . The consent allows to take a tissue sample , describe his or her state of health and pedigree, to encode the genome and to use the information for genetic research, public health research and statistical purposes . The agreement is formalized in writing. Data protection is guaranteed in the EBB by the application of procedural guidelines for all data processing, which are also adhered to in this study. The principle of not doing harm The present study has a research design developed by competent and competent scientists, and has the latest technology for performing analyses . Implementing high-level technology ensures the accuracy and high quality of the research. There is no threat to the data of individuals, as it is not used outside the protocol, and biological material is not used. This study does not cause psycholo gical stress to gene donors. The principle of charity Since this study gene donors are not contacted initially no direct benefit can be obtained . However, social charity is manifested through scientific innovation and the improvement of the health system. In the long term, the application of research results will be towards more personalized treatment, prevention and diagnosis, which will also benefit each individual personally. The principle of justice This research creates a prerequisite for more effective, safer and better access to health care in society. EBB is a population-based biobank, where different social and age groups are represented, the distribution of gender and other demographic features in the EBB quite well reflect the composition of the entire Estonian population. Thus, all members of society benefit from research. S cientists use only pseudonymis ed data and no data re-encoding by foreign partners will be permitted . Therefore, there is no threat to the dene donors’ privacy. Concerning ethical aspects of the PRECISE4Q research, as agreed with European Commission on signing the Grant Agreement, an EU-leading institution on the ethics and legal issues of predictive modelling and big data , ETH Zürich (Agatha Keller)), is responsible for this topic. Contact person for PRECISE4Q matters is Alessandro Blasimme (
[email protected] ). Ethical issues arising in Estonia will be directed to the PI of the study, Lili Milani (
[email protected]). 10. INFORMATION ON EARLIER OR SIMULTANEOUS ASSESSMENT OR ON APPROVAL OF THE SAME PROJECT ELSEWHERE The data has been created during the domestic research project “Precise 4Q Personalised Medicine by Predictive Modeling for Better Quality of Life”; permission for research 289/T-25 by the Research Ethics Committe e of the University of Tartu for the Institute of Genomics and Institute of Computer Science, University of Tartu. During this research a data table has been created (Annex 11.4; structure of the data table). 11. ANNEXES : 11.1 The CV s of the investigator s are attached to the application as separate files. 11.2 Form for informing and informed consent of the subject or his or her legal representative Not submitted because the study is database-based (Based on the Statute of UT REC , approved by the University of Tartu Decree No 14 of 7 July 2010, as amended by Decree No 65 of 10 December 2015 and O rder No 21 of 29 December 2017) . 11.3 Research articles relat ed to the topic of the research Parmar P, Lowry E, ... Lili Milani, Silva Kasela, ... Krista Fischer, ... Jarvelin M_R, Sebert S. BIOS Consortium, GLOBAL Meth QTL. "Association of maternal prenatal smoking GFI1-locus and cardio-metabolic phenotypes in 18,212 adults" EBIOMEDICINE, 2018, 38, pp. 206-216. DOI: 10.1016 / j.biom .2018.10.066 Roselli , C; Chaffin, MD; ... Tõnu Esko, ... Maris Teder-Laving ... Lunetta , L and Ellinor , T. “Multi-ethnic genome-wide association study for atrial fibrillation”. Nature Genetics, 2018, 50 (9), pp. 1225-1233. Doi : https://doi.org/10.1038/s41588-018-0133-9 Saar, A; Marandi , T; Ainla , T; Fischer, K; Blöndal , M; Eha , J. The risk-treatment paradox in non-ST-elevation myocardial infarction patients according to their estimated GRACE risk. International Journal of Cardiology, 2018, 272, pp. 26-32. DOI: https://doi.org/10.1016/j.ijcard.2018.08.015 11.4 Structure of the data table to be released to partners General Information sex nationality date of birth (year) BMI physical activity diet alcohol consumption smoking drug use mental stress History of diseases diabetes high blood pressure carotid artery stenosis atrial fibrillation dyslipidemia and metabolic syndrome stroke transient ischemic attack amauro sis fugax heart failure Comorbidity d iabetes high blood pressure carotid artery stenosis atrial fibrillation dyslipidemia and metabolic syndrome stroke transient ischemic attack amauro sis fugax heart failure Diagnosis of the stroke damaged side start of status (date and time) date and time of admission to hospital / stroke department date and time of departure from hospital / stroke department date and time of arrival in hospital / stroke department came with ambulance date of death woke up with symptoms Cerebral ischemia hemorrhage region History of procedures (including dates) Computer CT scan Date and time of CT Radiological diagnosis of CT Date and time of the planned KT Brain MRI Date and time of MRI MRI radiological diagnosis Date and time of the planned MRI Computer tomography of the head and angiography Area of procedure Date and time of CT angiography Radiological diagnosis of CT angiography The date and time of the planned CT angiography Head MRI and a ngiography Area of procedure Date and time of MRI angiography Radiological diagnosis of MRI angiography The date and time of the planned MRI angiography Carotid ultrasound Date and time of sleep artery UH Radiological diagnosis of sleep artery UH The date and time of the planned carotid artery UH Long-term ECG Date and time of long-term ECG ECG diagnosis The date and time of the planned long-term ECG Speech Disruption difficulty in swallowing assessment of speech function the date and time of the speech function evaluation reason why assessment of speech function was not performed evaluation of swallowing function date and time of evaluation of swallowing function the reason why the evaluation of the swallowing function was not performed Medicines antihypertensive drugs statins platelet inhibitors oral anticoagulants ASA ( e. g.Trombyl ) Clopidogrel (e.g. Plavix) Dipyridamol ( Persantin ) o ther platelet inhibitors (e.g., Brilique , Efient , Pletal , Possia ) Warfarin ( Waran ) a t the onset of warfarin treatment - INR value regardless of diagnosis Apixaban ( Eliquis ) Dabigatran ( Pradaxa ) Rivaroxaban ( Xarelto ) Edoxaban ( Lixiana ) Thrombolysis administered substance the date and time of the start of the procedure the date and time of the end of the procedure the reason why the procedure was not carried out Hemicranietomy Thrombectomy Genotypes chromosome no chromosome position rs number reference page an alternative allele Quality Score Metabol omi c data Clinical (b lood) Chemistry Measurements NIHSS score or equivalent (as evaluated by the doctor on the basis of the https://www.mdcalc.com/nih-stroke-scale-score-nihss) mRS score or equivalent (Oxford Handicap Score (OHS), as evaluated by the doctor) 11.5 Signatures of the authorized persons, researchers and collaborators Pages 16-2 5 Estonia, Tartu, University of Tartu -------------------------------------------- Date: Mait Metspalu Director of the Institute of Genomics -------------------------------------------- Date: Dage Särg -------------------------------------------- Date: Sven Laur -------------------------------------------- Date: Lili Milani Responsible investigator -------------------------------------------- Date: Toomas Haller Germany, Berlin, Charité University Medicine -------------------------------------------- Date: Dietmar Frey Founding director of the Charité Predictive Modeling in Medicine Lab Researcher -------------------------------------------- Date: Vince Istvan Madai -------------------------------------------- Date: Michelle Livne -------------------------------------------- Date: Tabea Kossen -------------------------------------------- Date: Hüseyin Camalan Austria, Graz, University of Graz -------------------------------------------- Date: Andrea Berghold Head of the Institute for Medical Informatics, Statistics and Documentation -------------------------------------------- Date: JOSE ANTONIO MIÑARRO GIMENEZ -------------------------------------------- Date: Catalina Martínez Costa Spain, Barcelona, QMENTA -------------------------------------------- Date: Paulo Rodrigues CTO of QMENTA Researcher -------------------------------------------- Date: Matthew Rowe -------------------------------------------- Date: Irina Sánchez Ireland, Technology University Dublin -------------------------------------------- Date: John D. Kelleher Head of the Institute for Medical Informatics, Statistics and Documentation Researcher Germany, AOK Nordost Health Insurance, Potsdam -------------------------------------------- Date: Marek Rydzewski AOK Nordost Germany, Berlin, University of Applied Science, Data Science Institute -------------------------------------------- Date: Thomas Peter Zahn University of Applied Science, Data Science Institute Researcher Sweden, Linköping University, Linköping -------------------------------------------- Date: Gunnar Cedersund PI of the ISB Group Researcher -------------------------------------------- Date: Kajsa Tunedal -------------------------------------------- Date: Tilda Herrgårdh Germany, German Research Center for Artificial Intelligence (DFKI), Saarbrücken -------------------------------------------- Date: Günter Neumann Research Fellow at DFKI Researcher -------------------------------------------- Date: Saadullah Amin Spain, University of Murci a -------------------------------------------- Date: Jesualdo Tomás Fernández Breis Professor United Kingdom, University of Edinburgh -------------------------------------------- Date: 18.05.2021 Cathie Sudlow Professor of Neurology & Clinical Epidemiology, University of Edinburgh, Director of the BHF Data Science Centre -------------------------------------------- Date: 18.05.2021 Kristiina Rannikmäe